A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial)

Japanese Journal of Clinical Oncology

Volumn 41, Issue 2, 2011, Pages 283-286

  Kodera, Yasuhiro ^a   Imano, Motohiro ^b   Yoshikawa, Takaki ^c   Takahashi, Naoto ^d   Tsuburaya, Akira ^c   Miyashita, Yumi ^e   Morita, Satoshi ^f   Nakao, Akimasa ^a   Sakamoto, Junichi ^a   Sasako, Mitsuru ^g  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Nonprofit Organization ECRIN   (Japan)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Clinical trial; Gastric cancer; Paclitaxel

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; JAPAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEASIBILITY STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; JAPAN; PACLITAXEL; PATIENT SELECTION; PERITONEAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STOMACH NEOPLASMS;

EID: 79251606859     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq187     Document Type: Article

References (8)

1. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250:242-6.
2. Markman M, Brady M, Spirtos N, Hanjani P, Rubin S. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-4.
3. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-5.
4. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009;76:311-4.
5. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, et al. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 2007;54:960-3.
6. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67-70.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) a phase III trial. Lancet Oncol 2008;9:215-21.
8. Simon R, Wittes R, Ellenberg S. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-81.